an outcome reflecting the patient’s perspective on treatment-related adverse events in people with rheumatic and musculoskeletal diseases enrolled in clinical trials. It focuses on the severity, frequency, and interference of symptoms (as distinct from “signs”) across different body systems. This outcome captures how tolerable or disruptive side effects are from the patient’s point of view, providing a fuller picture of a therapy’s overall impact.